Stem Pharm Co-Founder Bill Murphy delivered the Plenary talk, entitled Robust Assembly of Human Tissues for Disease Modeling and Discovery, at the Society of Toxicology 2019 Annual Meeting in Baltimore, MD on 11March2019. https://www.toxicology.org/education/pw/lec/AM19_Plenary_Session.asp
Stem Pharm has been awarded a Phase I NIH SBIR grant (1R43NS102088; PI: Dr. Lebakken) through the National Institute Of Neurological Disorders And Stroke (NINDS) entitled: Synthetic hydrogels for biomanufacturing of iPSC-derived neural cells for precision medicine. This effort will use Stem Pharm’s hydrogel coatings for efficient differentiation and maturation of iPSC-derived neurons that can be used for modeling neurodevelopmental disorders, discovering new precision therapies, and screening for toxins in life science and pharma applications..
Stem Pharm has been awarded a Phase I NIH SBIR grant (R43ES029897; PI: Dr. Lebakken) through the National Institute of Environmental Health Sciences entitled: Synthetic biomaterials designed for the generation and maintenance of mouse neural organoids for in vitro toxicity screening. This effort will use Stem Pharm’s hydrogel platform in the formation and validation of advanced in vitro neural models that have the potential to drastically reduce the use of live animals for toxicity testing.
Stem Pharm has been awarded an SBIR Advance grant to aid our technology commercialization efforts by the Wisconsin Economic Development Corporation (WEDC) and the University of Wisconsin-Extension’s Center for Technology Commercialization (CTC). https://wisconsinsbir.org/content/state-matching-grants-boost-six-high-tech-small-businesses
Stem Pharm hydrogel technologies are the focus of a recently published manuscript, "Versatile synthetic alternatives to Matrigel for vascular toxicity screening and stem cell expansion" published in Nature Biomedical Engineering with an accompanying 'story behind the paper' written by Eric Nguyen. https://www.nature.com/articles/s41551-017-0096 https://nbmecommunity.nature.com/channels/541-behind-the-paper
Stem Pharm has been awarded a $291,000 Phase I SBIR grant from the National Center For Advancing Translational Sciences of the National Institutes of Health. http://news.wisc.edu/spinoff-harnesses-stem-cells-for-new-medical-uses/
The Wisconsin State Journal highlighted a story about Stem Pharm’s recent participation in the Road to Global Entrepreneurship Summit (GES) (https://madison.com/wsj/business/two-madison-biotech-leaders-to-represent-the-midwest-at-a/article_0c7274f5-5d24-519b-8200-dc4c35b63fae.html). Steve Visuri showcased Stem Pharm during a luncheon “pitch” session at the event in March and was awarded with a paid trip to GES 2019 in The Hague, Netherlands in June. GES 2019 will focus on global opportunities for entrepreneur-led innovation, where 1,200 hand-picked entrepreneurs will engage with 300+ investors as well as policymakers, corporate partners and thought leaders to accelerate their solutions. (https://www.ges2019.org/)
Stem Pharm is featured in a segment that will appear on the Big10 Network celebrating the 20th anniversary of the publication of “Embryonic Stem Cell Lines Derived from Human Blastocysts,” the seminal paper published in Science by James Thomson at UW-Madison. The video highlights our efforts to translate this important discovery to clinical use in therapeutics and drug development. https://youtu.be/1qLCQillhPo
Feature on our hydrogel technologies, "Advance furthers stem cells for use in drug discovery, cell therapy" by David Tenenbaum https://medicalxpress.com/news/2017-07-advance-furthers-stem-cells-drug.html
Stem Pharm feature on Xconomy. http://www.xconomy.com/wisconsin/2017/05/18/stem-pharm-aims-to-add-to-madisons-stem-cell-past-with-biomaterials/
Stem Pharm presented a poster on our Vascular Tubulogenesis model at the 2019 Society of Toxicology Annual Meeting (https://www.toxicology.org/events/am/AM2019/index.asp).
Connie Lebakken will be delivering a talk on Stem Pharm's hydrogel and organoid technologies at the SelectBio 3D-Culture & Organoids conference in Coronado Island, CA on Oct. 4-5. 2018. This conference brings together researchers from around the world focusing on emerging organoid technologies and applications which is gaining much interest in the drug discovery field. (http://selectbiosciences.com/conferences/index.aspx?conf=3DORGAN2018)
Stem Pharm's Co-founder Dr. Connie Lebakken will be presenting a talk on Stem Cells, Regenerative Medicine and Stem Pharm Technology in the Disruptive (r)Evolution Showcase as part of the Badger Startup Summit on Wednesday Aug 22, 2018. (https://badgerstartup.com/)
Stem Pharm will be attending the Advanced Regenerative Manufacturing Institute (ARMI)/BioFabUSA's Spring Summit June 6th and 7th, 2018 in Manchester, NH. The meeting will focus on the themes of 'Technology & Innovation," specifically within the areas of Cell Culture Scale Up, Automation and Measurement Technologies, Biofabrication and Long-Term Incubation Platforms, and Storage and Packaging. (https://www.armiusa.org/events/2018/3/28/yv4sxw08au0pmpa1m7rp63b1qswpyl)
Steven Visuri, PhD, Stem Pharm's VP of Business Development will be attending the BIO 2018 International Convention (http://convention.bio.org/) June 4-7, 2018 in Boston, MA, specifically to participate in BIO's One-on-One Partnering sessions with leaders in Business Development from biotech and pharma companies. If you will be attending BIO and want to schedule a meeting, use our Contact page to reach out to us.
Join our COO Connie Lebakken, PhD for a free webinar on Tuesday 05 June 2018 at 11:00am EDT sponsored by Thermo Fisher Scientific: Versatile Synthetic Substrates for Cellular Assay Development and 3D Organoid Culture and Screening. https://xtalks.com/webinars/versatile-synthetic-substrates-for-cellular-assay-development/
Connie Lebakken, PhD, Stem Pharm's COO, will be a panelist at the Environmental Protection Agency's (EPA) 3rd Annual STAR (Science to Achieve Results) Organotypic Culture Models (OCM) for Predictive Toxicology Research Centers Progress Review: Implementation of Microphysiological Systems in Toxicological Assessments on May 22 and 23, 2018 in Durham, NC. The panel includes experts from academia and industry proving insight into the topic of Applications and Implementation of Microphysiological Systems as New Alternate Methods.
Stem Pharm's Jeff Nelson, Ph.D. will be presenting a poster entitled "Designed Biomaterials for Assay Development and Organoid Culture" at the Keystone Symposia’s Organs- and Tissues-on-Chips Conference on April 8-12, 2018 in Big Sky, MT (http://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1514).
Stem Pharm will be attending the 57th Annual Society of Toxicology (SOT) Meeting and ToxExpo at the Henry B. González Convention Center in San Antonio, Texas (March 11-15, 2018; https://www.toxicology.org/events/am/am2018/). If you would like to meet with us please contact us through our contact portal.
Stem Pharm will be attending the High-Content Analysis & 3D Screening Conference (November 6-8, 2017 in Cambridge, MA). If you would like to meet with us at either of these meetings, please contact us through our contact portal. For your convenience, here is the link to the meeting. http://www.highcontentanalysis.com/
Stem Pharm presented at the 3D CNS Disease Modeling Workshop sponsored by the National Institute of Health on November 11, 2016. https://www.ninds.nih.gov/News-Events/Events/3D-CNS-Disease-Modeling-Workshop